Evidence map›Paper›PMID 28741618›Full record

ReviewNature reviews. Clinical oncology2017

The immune contexture in cancer prognosis and treatment.

Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,423 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,423citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,423 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. A Versatile Anti-CXCR5 Monoclonal Antibody (CxCurrent issues in molecular biology · 2026
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

1,363 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wolf H FridmanCancer, Immune Control and Escape Team, INSERM UMRS 1138, Cordeliers Research Centre.
Laurence ZitvogelINSERM U1015, Institut Gustave Roussy Cancer Campus (GRCC), 14 rue Édouard Vaillant, 94805 Villejuif Cedex, France.
Catherine Sautès-FridmanCancer, Immune Control and Escape Team, INSERM UMRS 1138, Cordeliers Research Centre.
Guido KroemerParis Descartes University (Paris 5), Sorbonne Paris Cité, INSERM UMRS 1138, Cordeliers Research Centre.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response. As a result, the immune contexture, which is determined by the density, composition, functional state and organization of the leukocyte infiltrate of the tumour, can yield information that is relevant to prognosis, prediction of a treatment response and various other pharmacodynamic parameters. Several complementary technologies can be used to explore the immune contexture of tumours, and to derive biomarkers that could enable the adaptation of individual treatment approaches for each patient, as well as monitoring a response to anticancer therapies.

Indexed as

Tumor EscapeTumor MicroenvironmentAnimalsBiomarkers, TumorHumansImmunotherapyLymphocytes, Tumor-InfiltratingMonitoring, ImmunologicNeoplasmsPredictive Value of TestsTreatment OutcomeBiomarkers, Tumor

Identifiers

PMID28741618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.